Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianjun Yu

Showing results (311-320 of 325) with videos related to

Pageof 33
Sort By:
BMC Medicine|March 25, 2022
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancerBlossom Mak, Hui-Ming Lin, Edmond M Kwan, et al.
Ebiomedicine|October 17, 2021
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinaseHui-Ming Lin, Blossom Mak, Nicole Yeung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2014
Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancersPablo D Garcia, John L Langowski, Yingyun Wang, et al.
Cancer Cell|June 10, 2008
The role of SPINK1 in ETS rearrangement-negative prostate cancersScott A Tomlins, Daniel R Rhodes, Jianjun Yu, et al.
Journal of Neurointerventional Surgery|November 10, 2021
Predictors of unfavorable outcome in stent-assisted coiling for symptomatic unruptured intracranial spontaneous vertebral artery dissecting aneurysms (uis-VADAs): results from a multicenter studyKaijun Zhao, Rui Zhao, Xinjian Yang, et al.
Science (New York, N.Y.)|February 26, 2016
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5Konstantinos J Mavrakis, E Robert McDonald, Michael R Schlabach, et al.
JAMA Oncology|November 14, 2024
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical TrialYing Cheng, Wei Zhang, Lin Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2022
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)Zhijie Wang, Lin Wu, Baolan Li, et al.
Future Oncology (London, England)|December 4, 2024
A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)Zhijie Wang, Lin Wu, Baolan Li, et al.
Journal of Cancer Research and Therapeutics|October 2, 2020
Expert consensus workshop report: Guidelines for thermal ablation of thyroid tumors (2019 edition)Dong Xu, Minghua Ge, Ankui Yang, et al.
Pageof 33

Showing results (311-320 of 325) with videos related to

Sort By:
Pageof 33
BMC Medicine|March 25, 2022
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancerBlossom Mak, Hui-Ming Lin, Edmond M Kwan, et al.
Ebiomedicine|October 17, 2021
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinaseHui-Ming Lin, Blossom Mak, Nicole Yeung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2014
Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancersPablo D Garcia, John L Langowski, Yingyun Wang, et al.
Cancer Cell|June 10, 2008
The role of SPINK1 in ETS rearrangement-negative prostate cancersScott A Tomlins, Daniel R Rhodes, Jianjun Yu, et al.
Journal of Neurointerventional Surgery|November 10, 2021
Predictors of unfavorable outcome in stent-assisted coiling for symptomatic unruptured intracranial spontaneous vertebral artery dissecting aneurysms (uis-VADAs): results from a multicenter studyKaijun Zhao, Rui Zhao, Xinjian Yang, et al.
Science (New York, N.Y.)|February 26, 2016
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5Konstantinos J Mavrakis, E Robert McDonald, Michael R Schlabach, et al.
JAMA Oncology|November 14, 2024
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical TrialYing Cheng, Wei Zhang, Lin Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2022
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)Zhijie Wang, Lin Wu, Baolan Li, et al.
Future Oncology (London, England)|December 4, 2024
A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)Zhijie Wang, Lin Wu, Baolan Li, et al.
Journal of Cancer Research and Therapeutics|October 2, 2020
Expert consensus workshop report: Guidelines for thermal ablation of thyroid tumors (2019 edition)Dong Xu, Minghua Ge, Ankui Yang, et al.
Pageof 33